Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03988036 |
| Title | A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) |
| Acronym | Keyriched-1 |
| Recruitment | Completed |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | West German Study Group |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | DEU |